Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

147.36USD
19 Jan 2018
Change (% chg)

$0.44 (+0.30%)
Prev Close
$146.92
Open
$147.54
Day's High
$147.64
Day's Low
$146.43
Volume
4,046,939
Avg. Vol
1,951,787
52-wk High
$148.32
52-wk Low
$110.76

Select another date:

Thu, Jan 18 2018

Photo

U.S. court invalidates Johnson & Johnson cancer drug patent, hitting UK's BTG

NEW YORK A U.S. administrative court invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc .

U.S. court invalidates J&J cancer drug patent, hitting UK's BTG

NEW YORK A U.S. administrative court invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc .

UPDATE 1-U.S. court invalidates J&J cancer drug patent, hitting UK's BTG

NEW YORK, Jan 18 A U.S. administrative court invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc.

Exclusive: J&J attracts Chinese interest for diabetes business in potential $3-4 billion deal - sources

HONG KONG Chinese bidders are circling a diabetes care business owned by the world's largest healthcare company Johnson & Johnson in a deal that could fetch up to $4 billion, five people with direct knowledge told Reuters.

Exclusive - J&J attracts Chinese interest for diabetes business in potential $3-4 billion deal: sources

HONG KONG Chinese bidders are circling a diabetes care business owned by the world's largest healthcare company Johnson & Johnson in a deal that could fetch up to $4 billion (2.90 billion pounds), five people with direct knowledge told Reuters.

Bayer, J&J win reversal of $28 million verdict in Xarelto lawsuit

A Pennsylvania state court judge on Tuesday overturned a $27.8 million jury award to an Indiana couple who accused Bayer AG and Johnson & Johnson of failing to warn of internal bleeding risks of their drug Xarelto, the companies said.

Bayer, J&J win reversal of $28 mln verdict in Xarelto lawsuit

Jan 9 A Pennsylvania state court judge on Tuesday overturned a $27.8 million jury award to an Indiana couple who accused Bayer AG and Johnson & Johnson of failing to warn of internal bleeding risks of their drug Xarelto, the companies said.

FDA issues recall on J&J heart device

The U.S. Food and Drug Administration on Tuesday issued a recall of a heart device made by a unit of Johnson & Johnson due to a faulty valve, following a recall by the company in June.

UPDATE 1-FDA issues recall on J&J heart device

Jan 2 The U.S. Food and Drug Administration on Tuesday issued a recall of a heart device made by a unit of Johnson & Johnson due to a faulty valve, following a recall by the company in June.

BRIEF-Johnson & Johnson Declares Cash Dividend For Q1 2018 Of $0.84 Per Share On Co's Common Stock

* JOHNSON & JOHNSON ANNOUNCES QUARTERLY DIVIDEND FOR FIRST QUARTER 2018

Select another date: